Novel involvement of leukotriene B₄ receptor 2 through ERK activation by PP2A down-regulation in leukotriene B₄-induced keratin phosphorylation and reorganization of pancreatic cancer cells

Biochim Biophys Acta. 2012 Dec;1823(12):2120-9. doi: 10.1016/j.bbamcr.2012.09.004. Epub 2012 Sep 24.

Abstract

Perinuclear reorganization via phosphorylation of specific serine residues in keratin is involved in the deformability of metastatic cancer cells. The level of leukotriene B₄ is high in pancreatic cancers. However, the roles of LTB₄ and its cognate receptors in keratin reorganization of pancreatic cancers are not known. LTB₄ dose-dependently induced phosphorylation and reorganization of Keratin 8 (K8) and these processes were reversed by LY255283 (BLT2 antagonist). BLT2 agonists such as Comp A and 15(S)-HETE also induced phosphorylation of serine 431 in K8. Moreover, Comp A-induced K8 phosphorylation and reorganization were blocked by LY255283. Gene silencing of BLT2 suppressed Comp A-induced K8 phosphorylation and reorganization in PANC-1 cells. Over-expression of BLT2 promoted K8 phosphorylation. Comp A promoted the migration of PANC-1 cells in a dose-dependent manner, and LY255283 blocked Comp A-induced migration, respectively. PD98059 (ERK inhibitor) suppressed Comp A-induced phosphorylation of serine 431 and reorganization of K8. Gene silencing of BLT2 suppressed the expression of pERK, and over-expression of BLT2 increased the expression of pERK even without Comp A. Comp A induced the expression of active ERK (pERK) and BLT2. These inductions were blocked by PD98059. Comp A decreased PP2A expression and hindered the binding of PP2A to the K8, leading to the activation of ERK. PD98059 suppressed the Comp A-induced migration of PANC-1 cells and BLT2 over-expression-induced migration of PANC-1 cells. Overall, these results suggest that BLT2 is involved in LTB(4)-induced phosphorylation and reorganization through ERK activation by PP2A downregulation, leading to increased migration of PANC-1 cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anesthetics, Inhalation / pharmacology
  • Blotting, Western
  • Cell Adhesion / drug effects
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Down-Regulation
  • Enzyme Activation
  • Ethers / pharmacology
  • Flavonoids / pharmacology
  • Flow Cytometry
  • Fluorescent Antibody Technique
  • Humans
  • Hydrocarbons, Fluorinated / pharmacology
  • Immunoprecipitation
  • Keratin-8 / metabolism*
  • Leukotriene B4 / pharmacology*
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 3 / metabolism*
  • Pancreatic Neoplasms / metabolism*
  • Pancreatic Neoplasms / pathology
  • Phosphorylation / drug effects
  • Protein Phosphatase 2 / antagonists & inhibitors
  • Protein Phosphatase 2 / metabolism*
  • RNA, Messenger / genetics
  • RNA, Small Interfering / genetics
  • Receptors, Leukotriene B4 / antagonists & inhibitors
  • Receptors, Leukotriene B4 / genetics
  • Receptors, Leukotriene B4 / metabolism*
  • Serine / chemistry
  • Serine / metabolism
  • Signal Transduction / drug effects
  • Tumor Cells, Cultured

Substances

  • Anesthetics, Inhalation
  • Ethers
  • Flavonoids
  • Hydrocarbons, Fluorinated
  • Keratin-8
  • LTB4R2 protein, human
  • RNA, Messenger
  • RNA, Small Interfering
  • Receptors, Leukotriene B4
  • Leukotriene B4
  • Serine
  • fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether
  • Mitogen-Activated Protein Kinase 3
  • Protein Phosphatase 2
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one